ATRX and oligodendroglioma: In addition, CIC, FUBP1, TERT promoter mutations and 1p/19q codeletion are observed more frequently in oligodendrogliomas than in astrocytic tumors [13–15] whereas ATRX and TP53 mutations are seen more frequently in grade II/III astrocytic tumors [16–18].